Vancouver-based Numinus to treat 20 PTSD patients with drug also known as ecstacy.
A B.C. psychedelics company has received federal approval to use MDMA to treat more than a dozen people suffering from post-traumatic stress disorder.
Numinus, a Vancouver-based health company specializing in psychedelic research, will treat 20 people suffering from PTSD using MDMA-assisted therapy. On Monday, it confirmed the study had received regulatory approval from Health Canada.
The move comes as a growing body of research attempts to uncover the health benefits of MDMA, particularly in treating PTSD. Previous clinical trials led by the Multidisciplinary Association for Psychedelic Studies (MAPS) showed that more than half of the subjects no longer qualified for a diagnosis of PTSD two months following treatment that included three sessions of MDMA-assisted therapy .
Full article at CBC News.